Celldex Therapeutics (CLDX) Leaps on Buy Rating

Celldex Therapeutics, Inc. (NASDAQ: CLDX) rose 9.3% to $4.37. Brean Capital assumed Celldex Therapeutics with a buy rating and a $16.00 price target. Share volume was 3.3 million, compared to an all-day average of two million